Neoadjuvant hormone therapy beneficial for patients with high-risk prostate cancer: Study
Intense neoadjuvant hormone therapy in patients with high-risk prostate cancer shows favorable pathologic responses, suggested a study published in The Journal of Urology.
A multicenter randomized phase 2 trial was conducted by McKay R et. al to investigate the influence of intense androgen deprivation on radical prostatectomy pathologic response and radiographic and tissue biomarkers in localized prostate cancer.
The researchers selected eligible patients with a Gleason score of ≥4+3=7, prostate-specific antigen >20 ng/mL or T3 disease and lymph nodes <20 mm.
The researchers recruited a total of 118 patients at 4 sites.
With the median age of 61 years, 94% of patients showed high-risk disease.
In Part 1, patients were randomized in the ratio of 1:1 to apalutamide, abiraterone acetate, prednisone, and leuprolide (AAPL) or abiraterone, prednisone, leuprolide (APL) for 6 cycles (1 cycle=28 days) followed by radical prostatectomy. Surgical specimens also were centrally reviewed. The primary outcome was to determine the rate of pathologic complete response or minimum residual disease (minimum residual disease, tumor ≤5 mm).
While, the secondary endpoints included prostate-specific antigen response, positive margin rate, and safety.
Magnetic resonance imaging and tissue biomarkers of pathologic outcomes were explored.
The results of the study are as follows:
· The combined pathologic complete response or minimum residual disease rate was 22% in the AAPL arm and 20% in the APL arm.
· No new safety signals were observed.
· There was low concordance and correlation between post-therapy magnetic resonance imaging assessed and pathologically assessed tumor volume.
· PTEN-loss, ERG positivity and the presence of intraductal carcinoma was associated with an extensive residual tumor.
Thus, the researchers concluded that Intense neoadjuvant hormone therapy in high-risk prostate cancer resulted in favorable pathologic responses (tumor <5 mm) in 21% of patients, which were similar between both the treatment arms.
Reference:
A study titled, "Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy before Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer" by McKay R et. al published in The Journal of Urology.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.